A detailed history of Ethic Inc. transactions in Genmab A/S stock. As of the latest transaction made, Ethic Inc. holds 18,461 shares of GMAB stock, worth $380,111. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,461
Previous 16,838 9.64%
Holding current value
$380,111
Previous $423,000 6.38%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.84 - $28.48 $38,692 - $46,223
1,623 Added 9.64%
18,461 $450,000
Q2 2024

Aug 13, 2024

SELL
$25.13 - $30.27 $40,785 - $49,128
-1,623 Reduced 8.79%
16,838 $423,000
Q1 2024

May 13, 2024

BUY
$26.43 - $32.77 $188,287 - $233,453
7,124 Added 62.84%
18,461 $552,000
Q4 2023

Feb 14, 2024

SELL
$27.94 - $35.44 $44,424 - $56,349
-1,590 Reduced 12.3%
11,337 $360,000
Q3 2023

Nov 14, 2023

SELL
$35.27 - $42.24 $9,276 - $11,109
-263 Reduced 1.99%
12,927 $455,000
Q2 2023

Aug 14, 2023

SELL
$37.4 - $42.94 $23,113 - $26,536
-618 Reduced 4.48%
13,190 $501,000
Q1 2023

May 12, 2023

SELL
$34.88 - $43.22 $81,723 - $101,264
-2,343 Reduced 14.51%
13,808 $521,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $123,336 - $171,721
3,649 Added 29.19%
16,151 $684,000
Q3 2022

Nov 14, 2022

BUY
$31.52 - $373.61 $89,296 - $1.06 Million
2,833 Added 29.3%
12,502 $402,000
Q2 2022

Aug 10, 2022

SELL
$26.83 - $38.57 $65,304 - $93,879
-2,434 Reduced 20.11%
9,669 $314,000
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $104,580 - $134,078
3,379 Added 38.73%
12,103 $438,000
Q4 2021

Feb 14, 2022

BUY
$35.87 - $47.12 $4,376 - $5,748
122 Added 1.42%
8,724 $345,000
Q3 2021

Nov 15, 2021

BUY
$41.55 - $48.72 $75,454 - $88,475
1,816 Added 26.76%
8,602 $376,000
Q2 2021

Aug 10, 2021

BUY
$32.88 - $44.57 $223,123 - $302,452
6,786 New
6,786 $277,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Ethic Inc. Portfolio

Follow Ethic Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ethic Inc. with notifications on news.